Counselling about heart disease risk and statin use for women with HIV should highlight the similar levels of risk for men and women with HIV when communicating the results of the REPRIEVE study, one of the study’s investigators told the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver, US, last week.
Advice also needs to make women aware of how the symptoms of heart disease differ in women and men.
Dr Markella Zanni, Director of Women’s Health Research in the Metabolism Unit at Massachusetts General Hospital, Boston, presented an overview of insights from the REPRIEVE trial into sex-related differences in cardiovascular risk in people with HIV.
Read the full story at Aidsmap.
Source : Aidsmap
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.